These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20428820)

  • 1. Histological features of extratumoral breast lesions as a predictive factor of familial breast cancer.
    Mangia A; Tommasi S; Bruno M; Malfettone A; D'Amico C; Zito FA; Paradiso A; Simone G
    Oncol Rep; 2010 Jun; 23(6):1641-5. PubMed ID: 20428820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic and therapeutic mastectomy in BRCA mutation carriers: can the nipple be preserved?
    Reynolds C; Davidson JA; Lindor NM; Glazebrook KN; Jakub JW; Degnim AC; Sandhu NP; Walsh MF; Hartmann LC; Boughey JC
    Ann Surg Oncol; 2011 Oct; 18(11):3102-9. PubMed ID: 21947588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
    Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
    Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.
    Arun B; Vogel KJ; Lopez A; Hernandez M; Atchley D; Broglio KR; Amos CI; Meric-Bernstam F; Kuerer H; Hortobagyi GN; Albarracin CT
    Cancer Prev Res (Phila); 2009 Feb; 2(2):122-7. PubMed ID: 19174581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
    Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.
    Plevova P; Cerna D; Balcar A; Foretova L; Zapletalova J; Silhanova E; Curik R; Dvorackova J
    Neoplasma; 2010; 57(4):325-32. PubMed ID: 20429623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.
    Fountzilas E; Konstantopoulou I; Vagena A; Apostolou P; Papadimitriou C; Christodoulou C; Tryfonopoulos D; Manousou K; Delimitsou A; Papamentzelopoulou M; Fountzilas G; Yannoukakos D; Fostira F
    Clin Breast Cancer; 2020 Apr; 20(2):152-159. PubMed ID: 31980407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectrum of histopathologic findings in risk-reducing bilateral prophylactic mastectomy in patients with and without BRCA mutations.
    Boyraz B; Ly A
    Hum Pathol; 2024 Sep; 151():105534. PubMed ID: 38000681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer.
    Noori SF; Gangi A; Nelson ME; Choi M; Mirzadehgan P; Bonk AK; Mirocha J; Amersi F; Giuliano AE
    Ann Surg Oncol; 2014 Oct; 21(10):3324-9. PubMed ID: 25047471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
    Heikkinen T; Kärkkäinen H; Aaltonen K; Milne RL; Heikkilä P; Aittomäki K; Blomqvist C; Nevanlinna H
    Clin Cancer Res; 2009 May; 15(9):3214-22. PubMed ID: 19383810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution's high-risk population.
    Meiss AE; Thomas M; Modesitt SC; Ring KL; Atkins KA; Mills AM
    Hum Pathol; 2018 Dec; 82():20-31. PubMed ID: 29958926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.
    Jackson SA; Davis AA; Li J; Yi N; McCormick SR; Grant C; Fallen T; Crawford B; Loranger K; Litton J; Arun B; Vande Wydeven K; Sidani A; Farmer K; Sanders M; Hoskins K; Nussbaum R; Esserman L; Garber JE; Kaklamani VG;
    Cancer; 2014 May; 120(10):1557-64. PubMed ID: 24522996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [BRCA1- and BRCA2- associated breast carcinomas].
    Ahrens P; Kreipe HH
    Pathologe; 2009 Dec; 30 Suppl 2():207-9. PubMed ID: 19795125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
    Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The case against BRCA 1 and 2 testing.
    Lin C; Sasaki T; Strumwasser A; Harken A
    Surgery; 2011 Jun; 149(6):731-4. PubMed ID: 21621683
    [No Abstract]   [Full Text] [Related]  

  • 18. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
    Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
    Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
    Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
    Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA-associated breast cancer: absence of a characteristic immunophenotype.
    Robson M; Rajan P; Rosen PP; Gilewski T; Hirschaut Y; Pressman P; Haas B; Norton L; Offit K
    Cancer Res; 1998 May; 58(9):1839-42. PubMed ID: 9581822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.